Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy
Authors:
- Martin BarainkaMBMartin Barainka
- Angelina ZhelevaAZAngelina Zheleva
- Angela Pérez-CerveraAPAngela Pérez-Cervera
- Helena VillanuevaHVHelena Villanueva
- Daniel Meraviglia-CrivelliDMDaniel Meraviglia-Crivelli
- Beatriz MorenoBMBeatriz Moreno
- Fernando PastorFernando Pastor
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Gobierno de Navarra (0011-1411-2024-000110)
- Instituto de Salud Carlos III (PI23/01120)
- Fundación Científica Asociación Española Contra el Cáncer (PRYES235096PAST)
This publication has 49 references indexed in Scilit:
- Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemiasCell, 2025
- Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesisCell Reports, 2023
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunityCell, 2021
- Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerCell, 2021
- Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine MethylationCancer Cell, 2019
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsCancer Cell, 2018
- Mechanism of Nonsense-Mediated mRNA Decay Stimulation by Splicing Factor SRSF1Cell Reports, 2018
- Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndromeCancer, 2018
- Systematic Analysis of Splice-Site-Creating Mutations in CancerCell Reports, 2018